자가면역질환 공동 연구 및 라이선싱 계약(2016-2026년)

Autoimmune Collaboration and Licensing Deals

Stop guessing autoimmune deal terms. Start using real evidence.

Autoimmune is one of the most competitive and fragmented partnering markets in biopharma - spanning 30+ diseases, multiple modalities, and highly variable deal structures.

If you're entering a deal without clear benchmarks, you're operating at a disadvantage.

This report gives you direct access to 1,000+ real-world autoimmune partnerships, so you can see exactly how deals are structured, valued, and negotiated across the market.

Know what a "market deal" actually looks like

Without real comparables, it's easy to overpay, undersell, or misjudge partner expectations.

With this report, you can:

• Anchor your deal with real precedent
• Understand what companies are actually agreeing to - not just what's announced
• Benchmark financial terms with confidence
• Compare upfronts, milestones, and royalty structures across autoimmune deals
• Understand variability across indications and stages
• See how deals differ between RA, IBD, dermatology, and beyond
• Pressure-test your assumptions before negotiations
• Validate your structure against real transactions
• Go beyond headline numbers - see how deals are really done
• Most sources stop at deal value. That's not enough.

This report gives you access to actual contract documents, so you can see:

• What rights are granted (and retained)
• How development and commercialization responsibilities are split
• How payments are triggered in practice
• Where risk, control, and flexibility sit in the agreement
• Because in autoimmune dealmaking, the structure matters as much as the price.
• Built for teams actively doing autoimmune deals

Whether you're licensing assets, partnering programs, or evaluating opportunities, this report helps you:

• Move faster with instant access to relevant comparables
• De-risk decisions using real deal evidence
• Strengthen your negotiation position
• Support internal strategy with credible market data
• What you get
• 1,000+ autoimmune collaboration and licensing deals
• Coverage across 30+ autoimmune diseases
• Financial terms, including upfronts, milestones, and royalties
• Fully searchable deal directory (by company, therapy, technology)
• Direct access to SEC-filed contract documents
• 500+ pages of structured deal analysis
• The bottom line
• Autoimmune dealmaking is complex - but your decision-making doesn't have to be.
• This report gives you the benchmarks, deal structures, and contract-level insight you need to structure better deals - and win them.
• Request a sample or speak to us about how this can support your current autoimmune deal work.

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in autoimmune dealmaking

• 2.1. Introduction
• 2.2. Autoimmune deals over the years
• 2.3. Autoimmune deals by deal type
• 2.4. Autoimmune deals by industry sector
• 2.5. Autoimmune deals by stage of development
• 2.6. Autoimmune deals by technology type

Chapter 3 - Financial deal terms for autoimmune deals

• 3.1. Introduction
• 3.2. Disclosed financials terms for autoimmune deals
• 3.3. Autoimmune deal headline values
• 3.4. Autoimmune deal upfront payments
• 3.5. Autoimmune deal milestone payments
• 3.6. Autoimmune deal royalty rates

Chapter 4 - Leading autoimmune dealmakers and deals

• 4.1. Introduction
• 4.2. Most active in autoimmune dealmaking
• 4.3. List of most active dealmakers in autoimmune
• 4.4. Top autoimmune deals by value

Chapter 5 - Autoimmune deal contract document directory

• 5.1. Introduction
• 5.2. Autoimmune partnering deals where contract document available

Chapter 6 - Autoimmune dealmaking by therapeutic target

• 6.1. Introduction
• 6.2. Deals by autoimmune therapeutic target
• Deal Directory
• Deal Directory - Autoimmune deals by company A-Z
• Deal Directory - Autoimmune deals by technology type
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

TABLE OF FIGURES

• Figure 1: Autoimmune deals since 2016
• Figure 2: Autoimmune deals by deal type since 2016
• Figure 3: Autoimmune deals by industry sector since 2016
• Figure 4: Autoimmune deals by stage of development since 2016
• Figure 5: Autoimmune deals by technology type since 2016
• Figure 6: Autoimmune deals with a headline value
• Figure 7: Autoimmune deals with upfront payment values
• Figure 8: Autoimmune deals with milestone payment
• Figure 9: Autoimmune deals with royalty rates
• Figure 10: Active autoimmune dealmaking activity since 2016
• Figure 11: Top autoimmune deals by value since 2016